BOC Sciences delivers complete testing and evaluation services for fatty acid synthase (FASN) inhibitors to aid drug discovery and development. Our advanced pharmacological testing platforms facilitate thorough evaluations of FASN inhibitors to determine their potency, selectivity, and mechanism of action. We provide services that concentrate on enzyme activity measurement, cellular impact analysis, and lipid-pathway exploration which allows accurate discovery of lead compounds and enhancement of current drug candidates. Our use of modern technologies that include biochemical assays as well as fluorescence-based assays and cellular models enables us to produce reliable and repeatable data. Our expert team customizes testing procedures to achieve specific research objectives which results in quick analytical feedback and valuable findings that boost your FASN-related therapeutic research.
In the pharmacological evaluation of fatty acid synthase inhibitors, researchers face several challenges. Ensuring target selectivity is crucial to avoid off-target effects, as FASN plays a key role in lipid biosynthesis. Accurately distinguishing the primary effects of FASN inhibition from potential off-target disruptions in lipid metabolism is another significant hurdle. Traditional pharmacological evaluation methods may not provide a comprehensive understanding of therapeutic potential, requiring more sophisticated testing approaches. Gaining insights into the molecular mechanisms of FASN inhibition is essential for optimizing drug efficacy. Additionally, profiling potential side effects is vital, as FASN is involved in various biological functions. Addressing these challenges is key to developing effective and safe FASN inhibitors.
Multidisciplinary experts with deep experience in FASN research ensure precise design and accurate experimental execution.
Equipped with cutting-edge instruments for cell, molecular, and in vivo studies to support in-depth pharmacological evaluation.
Offers validated cell and animal models across cancers and metabolic diseases for comprehensive efficacy and safety studies.
Tailored experimental plans aligned with client goals through close collaboration at every stage of the project.
Standardized workflows and multi-level data validation ensure reliable, reproducible, and high-quality results.
Streamlined project flow enables quick response, fast turnaround, and accelerated research timelines without compromising quality.
BOC Sciences provides comprehensive FASN inhibitor testing and pharmacological evaluation services to support drug discovery and development. Our services focus on evaluating the inhibitory effects and pharmacological properties of FASN inhibitors, enabling precise assessment of their potential therapeutic applications.
Measures the percentage inhibition of FASN enzyme activity at various concentrations, providing a key parameter for assessing compound potency.
Determines key enzyme kinetics values, such as Km and Vmax, to offer deeper insight into the mechanism of FASN inhibition and the compound's effect on enzyme function.
Evaluates the levels of Malonyl-CoA, a key intermediate in fatty acid synthesis, to assess the compound's impact on lipid biosynthesis pathways.
Measures the rate of fatty acid synthesis in cells after treatment with FASN inhibitors, helping to understand the compound's effect on metabolic processes.
Assesses the impact of FASN inhibitors on cell proliferation, using assays like MTT or XTT to evaluate compound efficacy in halting cell growth.
Analyzes the induction of apoptosis and cell cycle arrest in treated cells, evaluating the therapeutic potential of FASN inhibitors in modulating cell survival and growth.
Evaluates the impact of FASN inhibitors on tumor growth in vitro and in vivo, providing insights into their potential role in oncology therapeutics.
Monitors changes in intracellular lipid levels following FASN inhibition, offering critical information on how the compound alters lipid metabolism.
BOC Sciences has established an advanced pharmacological modeling platform to support drug discovery and development targeting fatty acid synthase. Our platform includes diverse in vitro and in vivo models tailored for evaluating FASN inhibitors across oncology, metabolic, neurodegenerative, and autoimmune disease research. We provide systematic and standardized methodologies to explore drug mechanisms, therapeutic efficacy, and safety, delivering reliable support for early-stage drug development and mechanistic studies.
| Cell Type | Description |
| Breast Cancer Cells (e.g., MCF-7) | Study FASN expression and inhibitor-induced apoptosis and chemotherapeutic sensitization. |
| Prostate Cancer Cells (e.g., LNCaP) | Evaluate FASN-mediated metabolic remodeling and cell cycle arrest. |
| Lung Cancer Cells (e.g., A549) | Assess anti-proliferative and anti-invasive effects of FASN inhibition. |
| Colorectal Cancer Cells (e.g., HCT116) | Investigate tumor suppression and stemness reduction via FASN blockade. |
| Ovarian Cancer Cells (e.g., SKOV3) | Examine cytotoxicity, apoptosis induction, and resistance reversal. |
| HepG2 / 3T3-L1 Cells | Analyze FASN's role in lipid metabolism, steatosis, and energy homeostasis. |
| Microglia / Neuronal Cells | Explore neuroprotective effects of FASN inhibition in neurodegenerative settings. |
| T Cells / Macrophages | Study immunometabolic modulation and inflammatory suppression by FASN inhibitors. |
| Model Type | Description |
| Breast Cancer Xenograft Model | Evaluate tumor growth suppression, apoptosis induction, and drug synergy in vivo. |
| Prostate Cancer Xenograft Model | Test therapeutic impact on androgen-independent tumor progression. |
| Lung Cancer Orthotopic Model | Investigate FASN inhibitor efficacy on invasion and metastasis. |
| Atherosclerosis ApoE-/- Mouse Model | Assess FASN inhibition on lipid accumulation, inflammation, and plaque formation. |
| Alzheimer's Disease Transgenic Model | Examine effects on amyloid deposition, neuroinflammation, and cognitive decline. |
| Collagen-Induced Arthritis Mouse Model | Evaluate anti-inflammatory and immunomodulatory potential in autoimmune disease. |
| Systemic Lupus Erythematosus Mouse Model | Study FASN regulation on antibody production and immune cell activity. |
BOC Sciences is equipped with state-of-the-art instrumentation platforms that support comprehensive and precise pharmacological evaluation of FASN inhibitors. Our robust analytical infrastructure integrates high-sensitivity molecular biology and biochemical analysis tools, enabling us to assess compound activity, metabolic impact, and therapeutic potential across various disease models. From real-time monitoring of gene expression to in-depth protein analysis and lipid quantification, our technologies ensure high accuracy, reproducibility, and efficiency in FASN-related research. These platforms empower us to deliver high-quality data that accelerates fatty acid synthase inhibitor development for cancer, cardiovascular, neurodegenerative, and autoimmune disorders.
| Real-Time Quantitative PCR (qPCR) | Liquid Chromatography–Mass Spectrometry (LC-MS) |
| Western Blot Detection System | Fluorescence Microscope |
| Flow Cytometer | Serum Biochemistry Analyzer |
BOC Sciences offers a comprehensive suite of assays tailored to assess the activity and inhibition of fatty acid synthase (FASN) both in vitro and in vivo. Our platform integrates biochemical, cellular, and mass spectrometry-based techniques, enabling researchers to quantitatively evaluate FASN activity, investigate downstream effects, and screen novel inhibitors with high precision and specificity. These assays support every phase of FASN-targeted drug discovery, from mechanism elucidation to efficacy validation.
This in vitro method measures FASN catalytic activity by detecting CoA released during fatty acid synthesis. The released CoA reacts with CPM dye, forming a fluorescent product. The fluorescence intensity directly correlates with enzyme activity. This highly sensitive and specific assay is ideal for evaluating FASN inhibitors in enzyme-based screening systems.
Utilizing monoclonal anti-FASN antibodies coated on microplates, this method quantifies FASN protein levels in biological samples. A biotin-labeled detection antibody, combined with HRP-streptavidin and colorimetric detection (e.g., TMB substrate), allows absorbance-based quantification. It is widely used to measure FASN expression in serum, tissue, or cell lysates from mice, rats, and other species.
We offer multiple assays to evaluate the biological effects of FASN inhibitors in cultured cells (e.g., SK-BR-3 cells). These include CCK-8 for proliferation, flow cytometry for apoptosis, immunoprecipitation for protein interaction, and Western blot for expression analysis. These assays help determine the cellular consequences of FASN modulation, supporting mechanistic and efficacy studies.
This chemoproteomic approach uses specific FASN-binding probes (e.g., FASN/PFASG affinity resins) to capture active FASN from complex samples. LC-MS/MS then identifies bound small molecules or confirms inhibitor binding. ABPP is ideal for discovering and validating covalent or selective FASN inhibitors with high target engagement.
BOC Sciences follows a streamlined and collaborative process to ensure reliable and reproducible FASN activity evaluation and inhibitor screening. Our full-service workflow covers everything from project planning to data interpretation, helping clients accelerate research with confidence.
Understanding Client Requirements
We begin by thoroughly communicating with clients to define project goals, target assays, sample types, and expected outcomes. This ensures alignment between technical feasibility and research objectives.
Experimental Design
Based on the project scope, our scientific team develops a customized experimental plan, including selection of detection methods (e.g., fluorescence, ELISA, GC-MS), control groups, and key performance indicators.
Sample Preparation and Handling
We assist clients in preparing appropriate biological samples or receive and process them in our facility under standardized protocols to maintain sample integrity and consistency.
Assay Execution
Experiments are carried out using validated procedures for FASN activity or expression analysis. This may include enzymatic assays, isotope labeling studies, mass spectrometry, or cell-based functional assays.
Data Collection and Analysis
Raw data are collected systematically and analyzed using statistical and bioinformatics tools. We ensure accurate interpretation of enzyme activity, expression levels, or cellular responses.
Report Preparation and Delivery
A detailed scientific report is compiled, including methodology, raw data, processed results, and interpretation. The report is reviewed internally for quality assurance before being delivered to the client.
BOC Sciences' FASN inhibitor pharmacological evaluation services can support new drug development across a wide range of diseases. These services can be particularly valuable in the following areas:
| Disease Area | Detail |
| Cancer | Breast Cancer: Inhibits tumor growth, invasion, and resistance. Enhances chemotherapy sensitivity. |
| Prostate Cancer: Reduces tumor growth and induces cell cycle arrest, especially in castration-resistant prostate cancer. | |
| Lung Cancer: Inhibits cell proliferation, migration, and invasion, promotes apoptosis, and may synergize with other anti-cancer drugs. | |
| Colorectal Cancer: Lowers cell survival, inhibits tumor growth and metastasis, and affects colorectal cancer stem cells. | |
| Ovarian Cancer: Suppresses cell growth, induces apoptosis, and demonstrates anti-tumor effects in animal models. | |
| Cardiovascular Diseases | Atherosclerosis: Regulates lipid metabolism, reduces LDL cholesterol, and alleviates vascular smooth muscle cell proliferation, slowing atherosclerosis. |
| Obesity-related Cardiovascular Disease: Reduces fat synthesis and storage, improves metabolic conditions, and lowers cardiovascular disease risk. | |
| Neurodegenerative Diseases | Alzheimer's Disease: Reduces amyloid plaque deposition, regulates lipid metabolism, and protects neurons from damage. |
| Parkinson's Disease: Modulates metabolic balance, reduces oxidative stress and inflammation, and protects dopaminergic neurons. | |
| Autoimmune Diseases | Rheumatoid Arthritis: Suppresses immune cell activation, reduces inflammation, and alleviates joint inflammation. |
| Systemic Lupus Erythematosus: Regulates immune cell function, inhibits autoantibody production, and potentially improves lupus treatment. |
What is the function of FASN?
Fatty acid synthase (FASN) is a key enzyme responsible for the de novo synthesis of fatty acids, providing essential lipids for cell membrane formation, energy storage, and signaling pathways.
What happens if fatty acid synthesis is inhibited?
Inhibition of fatty acid synthesis disrupts lipid homeostasis, impairs membrane integrity, induces metabolic stress, and can lead to reduced tumor growth or cell death, making it a promising therapeutic strategy in cancer and metabolic diseases.
Why are FASN inhibitors considered potential anticancer agents?
Many tumors exhibit elevated FASN expression to support rapid growth. FASN inhibitors can selectively impair cancer cell survival by blocking lipid synthesis, triggering apoptosis, and sensitizing tumors to other therapies.
What types of models are used for FASN inhibitor pharmacological testing?
FASN inhibitor testing commonly uses validated tumor cell lines (such as breast, lung, and colorectal cancers) and animal models, allowing comprehensive evaluation of efficacy, mechanism of action, and toxicity.
How does BOC Sciences support FASN inhibitor pharmacological testing?
BOC Sciences offers customized experimental design, advanced molecular assays, rich tumor models, strict quality control, and comprehensive data analysis to accelerate FASN inhibitor development and validation.
